Publication

Nanoparticles Dysregulate the Human Placental Secretome with Consequences on Angiogenesis and Vascularization.

Journal Paper/Review - May 20, 2024

Units
PubMed
Doi
Contact

Citation
Dugershaw-Kurzer B, Bossart J, Buljan M, Hannig Y, Zehnder S, Gupta G, Kissling V, Patrycja N, van Beijnum J, Griffioen A, Masjosthusmann S, Zühr E, Fritsche E, Hornung R, Rduch T, Buerki-Thurnherr T. Nanoparticles Dysregulate the Human Placental Secretome with Consequences on Angiogenesis and Vascularization. Adv Sci (Weinh) 2024:e2401060.
Type
Journal Paper/Review (English)
Journal
Adv Sci (Weinh) 2024
Publication Date
May 20, 2024
Issn Electronic
2198-3844
Pages
e2401060
Brief description/objective

Exposure to nanoparticles (NPs) in pregnancy is increasingly linked to adverse effects on embryo-fetal development and health later in life. However, the developmental toxicity mechanisms of NPs are largely unknown, in particular potential effects on the placental secretome, which orchestrates many developmental processes pivotal for pregnancy success. This study demonstrates extensive material- and pregnancy stage-specific deregulation of placental signaling from a single exposure of human placental explants to physiologically relevant concentrations of engineered (silica (SiO) and titanium dioxide (TiO) NPs) and environmental NPs (diesel exhaust particles, DEPs). This includes a multitude of secreted inflammatory, vascular, and endocrine placental factors as well as extracellular vesicle (EV)-associated proteins. Moreover, conditioned media (CM) from NP-exposed explants induce pronounced anti-angiogenic and anti-vasculogenic effects, while early neurodevelopmental processes are only marginally affected. These findings underscore the potential of metal oxide NPs and DEPs for widespread interference with the placental secretome and identify vascular morphogenesis as a sensitive outcome for the indirect developmental toxicity of different NPs. Overall, this work has profound implications for the future safety assessment of NPs for industrial, commercial, or medical applications in pregnancy, which should consider placenta-mediated toxicity by holistic secretomics approaches to ensure the development of safe nanotechnologies.